Cardiovascular risk among patients recovered from COVID-19 in the short and medium term: what does the current evidence conclude?
DOI:
https://doi.org/10.24265/horizmed.2023.v23n1.14Keywords:
coronavirus infections, risk groups, risk factors, cardiovascular disease, review literature as topicAbstract
Cardiovascular risk and diseases among patients recovered from COVID-19 is a recent field of study in the world medical literature and is also of vital importance because a large number of patients develop complications once the acute phase of the disease is over. The broad spectrum of myocardial injury in cardiovascular diseases can range from the
asymptomatic elevation of cardiac troponin levels to the development of fulminant myocarditis and/or circulatory shock, which can leave significant sequelae. Despite the fact that there is no clear strategy to treat cardiac events that occur during COVID-19 infection and taking into account that treatment is mainly aimed at relieving patients’ symptoms as they arise, the objective of this work was to find out and collect current evidence on this subject, so that readers can be offered a reference guide in Spanish that contributes to the development of their health profession. The methodology used was a literature search in databases including Medline, Scopus and ScienceDirect within a time window between 2019 and 2022. The main results revealed that the molecular and pathophysiological mechanisms involved in post-COVID-19 syndrome include the renin-angiotensin-aldosterone system since SARS-CoV-2 tropism is linked to angiotensin-converting enzyme 2. This causes an alteration of the neurohumoral response of the cardiovascular, renal and digestive systems,
generating deficits in the signaling pathways and causing direct damage to the heart, lungs and other organs. Post-COVID-19 syndrome, in general, is defined as the occurrence or persistence of symptoms three or four weeks after the acute phase of the disease. This could then be considered as a time window of risk and strict follow-up to assess in a
personalized way the risk among the different groups of patients, especially those with a past history of cardiovascular disease. The main results revealed disorders such as heart failure, arrhythmias, pericarditis and myocarditis, which require early detection and occur days or even weeks after the acute phase of COVID-19.
Downloads
References
Pires SM, Wyper GMA, Wengler A, Penalvo JL, Haneef R, Moran D, et al. Burden of Disease of COVID-19: Strengthening the Collaboration for National Studies. Front Public Health. 2022;10:907012.
Centers for Disease Control and Prevention. Cases, Data, and Surveillance [Internet]. Atlanta:CDC; 2020. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html
Gebru AA, Birhanu T, Wendimu E, Ayalew AF, Mulat S, Abasimel HZ, et al. Global burden of COVID-19: Situational analyis and review. Hum Antibodies. 2021;29(2):139-48.
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50.
Petersen SE, Friedrich MG, Leiner T, Elias MD, Ferreira VM, Fenski M, et al. Cardiovascular magnetic resonance for patients with COVID-19. JACC Cardiovasc Imaging. 2022;15(4):685-99.
Hassine IH. Covid-19 vaccines and variants of concern: A review. Rev Med Virol. 2022;32(4):e2313.
Tajbakhsh A, Gheibi SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345-57.
Ma L, Song K, Huang Y. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. J Cardiothorac Vasc Anesth. 2021;35(6):1860-5.
Su S, Chen R, Zhang S, Shu H, Luo J. Immune system changes in those with hypertension when infected with SARS-CoV-2. Cell Immunol. 2022;378:104562.
Choi M, Aiello EA, Ennis IL, Villa-Abrille MC. El SRAA y el SARS-CoV-2: el acertijo a resolver. Hipertens Riesgo Vasc. 2020;37(4):169-75.
Mavraganis G, Dimopoulou M, Delialis D, Bampatsias D, Patras R, Sianis A, et al. Clinical implications of vascular dysfunction in acute and convalescent COVID-19: A systematic review. Eur J Clin Invest. 2022;52(11):e13859.
Navarro-Ulloa OD, Picon-Jaimes YA, Conde-Cardona G, FernandezYepez LJ, Zabala-Carballo CI, Lopez-Garcia J, et al. Usefulness of 24hour ambulatory blood pressure monitoring in a population with high cardiovascular risk. Cir Cir. 2020;88(5):617-23.
LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, et al. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis. 2021;21(1):677.
Bolano-Romero MP, Sanchez-Erazo SD, Paez-Rincon LA, Charry-Borrero DA. Post COVID-19 cardiovascular syndrome: An entity that cannot go unnoticed in the post-COVID era. Arch de Medi. 2022;18(1):1-2.
Rueda-Ibarra L, Manrique-Gualdron AM, Bayona-Gamboa AJ, AcunaOcampo JD, Picon-Jaimes YA, Lozada-Martinez ID, et al. Acute coronary syndromes following COVID-19 vaccine application: Kounis syndrome or chance? Ann Med Surg. 2022;80:104188.
Liu F, Liu F, Wang L. COVID-19 and cardiovascular diseases. J Mol Cell Biol. 2020;13(3):161-7.
Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.
Stafie CS, Solomon SM, Sufaru IG, Manaila M, Stafie II, Melinte G, et al. Pathogenic connections in post-COVID conditions: What do we know in the large unknown? A Narrative Review. Viruses. 2022;14(8):1686.
De Arriba A, Alonso JL, Espineira A, Cabeza A, Gutierrez A, Diaz MA, et al. Assessment of SARS-CoV-2 infection according to previous metabolic status and its association with mortality and post-acute COVID-19. Nutrients. 2022;14(14):2925.
Davoudi F, Miyashita S, Yoo TK, Lee PT, Foster GP. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Crit Pathw Cardiol. 2022;21(3):123-9.
Ahamed J, Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest. 2022;132(15):e161167.
Timpau A, Miftode R, Leca D, Timpau R, Miftode I, Petris AO, et al. A Real Pandoraï¿1/2s Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19. Life (Basel). 2022;12(7):1085.
Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90.
Sisti N, Valente S, Mandoli GE, Santoro C, Sciaccaluga C, Franchi F, et al. COVID-19 in patients with heart failure: the new and the old epidemic. Postgrad Med J. 2021;97(1145):175-9.
Wang W, Wang C, Wang S, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619.
Samidurai A, Das A. Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. Int J Mol Sci. 2020;21(18):6790.
Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142(1):68-78.
Wu L, Oï¿1/2Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020;178:114114.
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;201(11):1372-9.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
Bourgonje AR, Abdulle AE, Timens W, Hillebrands J, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228-48.
Wiemken TL, McGrath LJ, Andersen KM, Khan F, Malhotra D, Alfred T, et al. Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events. Clin Infect Dis. 2022;76(3):e42-e50.
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7.
Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy J, Vander RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-6.
Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9.
Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5.
Blaess M, Kaiser L, Sauer M, Csuk R, Deigner H. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. Int J Mol Sci. 2020;21(14):4953.
Cheng H, Wang Y, Wang G. Organ-protective effect of angiotensinconverting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92(7):726-30.
Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020;5(11):1281-5.
Gasecka A, Pruc M, Kukula K, Gilis-Malinowska N, Filipiak KJ, Jaguszewski MJ, et al. Post-COVID-19 heart syndrome. Cardiol J. 2021;28(2):353-4.
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-73.
Lozada-Martinez ID, Pava-Barrios GA, Yoli-Garrido A, Leal-Buitrago A, Rodriguez-Medina N. Post-COVID-19 cardiovascular syndrome: What does the evidence tell us? J Pract Cardiovasc Sci. 2022;8:65-7.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32.
Dixit NM, Churchill A, Nsair A, Hsu JJ. Post-Acute COVID-19 Syndrome and the cardiovascular system: What is known? Am Heart J Plus. 2021;5:100025.
Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ï¿1/2Long-COVIDï¿1/2: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396-8.
Knight DS, Kotecha T, Razvi Y, Chacko L, Brown JT, Jeetley PS, et al. COVID-19: Myocardial Injury in Survivors. Circulation. 2020;142(11):1120-2.
Fu H, Zhang N, Zheng Y, Jiang N, Xu H, Xu R, et al. Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients. J Infect. 2021;83(1):119-45.
Clark DE, Parikh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, et al. COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR). Circulation. 2021;143(6):609-12.
Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1207-28.
Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2021;18(4):508-9.
Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-64.
Angeli F, Spanevello A, De Ponti R, Visca D, Marazzato J, Palmiotto G, et al. Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med. 2020;78:101-6.
Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866-78.
Moulson N, Petek BJ, Drezner JA, Harmon KG, Kliethermes SA, Patel MR, et al. SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. Circulation. 2021;144(4):256-66.
Wang TJ, Chau B, Lui M, Lam G, Lin N, Humbert S. Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for COVID-19. Am J Phys Med Rehabil. 2020;99(9):769-74.
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-54.
Greenhalgh T, Knight M, Aï¿1/2Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.
Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for ecoepidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022;99:106589.
Rodriguez-Hernandez YA, Villamizar-Gomez FJ, Mantilla-Pardo JC, Robledo-Arias JS, Rahman S, Lozada-Martinez ID, et al. Post-COVID 19 neurological syndrome: The need to define a cut-off score between the acute and post-COVID 19 phases. Ann Med Surg (Lond). 2021;71:102983.
Lozada-Martinez ID, Diaz-Castillo OJ, Pearson-Arrieta AC, GaleanoBuelvas A, Moscote-Salazar LR. Post-COVID 19 neurological syndrome: A new risk factor that modifies the prognosis of patients with dementia. Alzheimers Dement.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
